TD Cowen raises target for Twist Bioscience stock to USD 190.00

Published on 10/15/2026 at 12:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Twist Bioscience stock was at EUR 128.08 on October 15, 2026. Fiscal third-quarter revenue rose 23.20 percent to USD 118.38 million.

Analyst target and operating results

TD Cowen lifted its Twist Bioscience target from USD 115.00 to USD 190.00 on October 13, 2026.
Fiscal third-quarter revenue reached USD 118.38 million, up 23.20 percent year over year.
Twist Bioscience stock traded at EUR 128.08 at 12:50 p.m. CEST at Lang & Schwarz on October 15, 2026.

TWST, US90184D1000, Illustration mit AI erstellt.

Twist Bioscience (ISIN US90184D1000) drew a higher USD 190.00 price target from TD Cowen on October 13, 2026, up from USD 115.00, while keeping a Buy rating, according to Markets Insider. The move puts analyst expectations ahead of the companys latest reported quarter, which showed faster revenue growth but a continuing loss.

Target rises as results set the test

Twist Bioscience reported fiscal third-quarter revenue of USD 118.38 million for the period ended June 30, 2026, a 23.20 percent year-over-year increase. The company reported a loss of USD 35.05 million and diluted earnings per share of minus USD 0.56 for the same period, according to InsiderTrades.com.

The revenue result exceeded the USD 114.55 million analyst expectation cited by InsiderTrades.com, but the earnings-per-share loss was wider than the USD 0.51 consensus loss. That combination makes execution and the path to profitability central to the higher valuation case.

Three dated signals shape TWST

On August 4, 2026, Twist Bioscience announced a USD 300.00 million public offering, according to Twist Bioscience. On October 9, 2026, CFO Adam Laponis sold 2,462 shares at an average USD 156.30, according to InsiderTrades.com. On October 13, 2026, TD Cowen raised its target to USD 190.00 from USD 115.00, according to Markets Insider.

What does the target mean for valuation?

Investing.com listed a USD 163.67 average 12-month target from 12 analysts on October 15, 2026, with TD Cowen at USD 190.00 and Canaccord at USD 205.00. The spread shows that the bullish view is not uniform, even as the latest quarterly revenue growth supplies a concrete operating measure for the debate.

Price stays below the US quote

Twist Bioscience was trading at EUR 128.08 at Lang & Schwarz on October 15, 2026 at 12:50 p.m. CEST. The Nasdaq quote was last at USD 148.16 on October 14, 2026 at 4:00 p.m. ET, while the 52-week Nasdaq range was USD 23.30 to USD 219.71.

The further course of trading is shown by the continuously updated real-time quote of Twist Bioscience stock.